Francesca Penagini
Overview
Explore the profile of Francesca Penagini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calcaterra V, Penagini F, Rossi V, Abbattista L, Bianchi A, Turzi M, et al.
Front Endocrinol (Lausanne)
. 2025 Feb;
16:1425241.
PMID: 39968296
Inflammatory bowel diseases (IBD) represent chronic inflammatory multisystemic disorders that primarily involve the gastrointestinal tract. Patients with ulcerative colitis (UC) and Crohn's disease (CD) exhibit a higher prevalence of thyroid...
2.
Penagini F, Lonoce L, Abbattista L, Silvera V, Rendo G, Cococcioni L, et al.
Pharmacol Res
. 2023 Sep;
196:106935.
PMID: 37748559
Inflammatory bowel diseases (IBDs) including Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD-U) are chronic inflammatory disorders which can affect the gastrointestinal tract. Anti-tumor necrosis factors...
3.
Borsani B, Biganzoli G, Penagini F, Bosetti A, Pendezza E, Perico V, et al.
Front Pediatr
. 2023 Sep;
11:1097152.
PMID: 37681200
Introduction: Energy requirements are difficult to estimate in children with cerebral palsy (CP). Resting energy expenditure (REE), necessary to implement personalized nutritional interventions, is most commonly estimated using prediction formulae...
4.
Cheli S, Savino D, Penagini F, Zuccotti G, Zuin G, Clementi E, et al.
Pharmaceutics
. 2023 Jul;
15(7).
PMID: 37514022
Therapeutic drug monitoring (TDM) is a useful tool for optimising the use of anti-TNFα inhibitors in patients with inflammatory bowel diseases (IBDs). Recently, point-of-care methods for the quantification of drug...
5.
Cheli S, Savino D, De Silvestri A, Norsa L, Sansotta N, Penagini F, et al.
Pharmacogenomics J
. 2023 May;
23(5):140.
PMID: 37231043
No abstract available.
6.
Cheli S, Savino D, De Silvestri A, Norsa L, Sansotta N, Penagini F, et al.
Pharmacogenomics J
. 2023 Apr;
23(5):112-118.
PMID: 37016150
Anti-tumor necrosis factor alpha (anti-TNFα) inhibitors are used extensively for the management of moderate to severe inflammatory bowel disease (IBD) in both adult and pediatric patients. Unfortunately, not all patients...
7.
Lionetti E, Pjetraj D, Gatti S, Catassi G, Bellantoni A, Boffardi M, et al.
Dig Liver Dis
. 2023 Jan;
55(5):608-613.
PMID: 36682923
Background: Celiac disease is a common lifelong disorder. Recent studies indicate that the number of clinically detected cases has increased over the last decades, however little is known about changes...
8.
Penagini F, Calcaterra V, Dilillo D, Vandoni M, Gianolio L, Gatti A, et al.
Children (Basel)
. 2022 Sep;
9(9).
PMID: 36138708
Background: Inflammatory bowel disease (IBD) patients show a higher risk of developing metabolic and cardiovascular diseases due to the presence of systemic low-grade chronic inflammation. Exercise can improve cardiovascular fitness...
9.
Borsani B, De Santis R, Perico V, Penagini F, Pendezza E, Dilillo D, et al.
Nutrients
. 2021 Oct;
13(10).
PMID: 34684400
Carrageenan (CGN) is a high molecular weight polysaccharide extracted from red seaweeds, composed of D-galactose residues linked in β-1,4 and α-1,3 galactose-galactose bond, widely used as a food additive in...
10.
Gatti S, Del Baldo G, Catassi G, Faragalli A, Aloi M, Bramuzzo M, et al.
Sci Rep
. 2021 Sep;
11(1):18076.
PMID: 34508152
Improving the quality of life (QoL) is crucial in the management of pediatric inflammatory bowel disease (IBD). We aimed to (1) Validate the IMPACT-III questionnaire in Italian IBD children; (2)...